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Lactate dehydrogenase (LDH): LDH is localised in the 
cytoplasm of cells and is thus extruded into the serum 
when cells are damaged. The total LDH is increased in 
viral or toxic hepatitis, extrahepatic biliary obstruction, 
acute necrosis of the liver and liver cirrhoses.
Tests of Cholestases
Gamma Glutamyl Transferase (GGT): GGT is 
a hepatic microsomal enzyme. Chronic ingestion 
of alcohol or drugs induces microsomal enzyme 
production. GGT permits differentiation of liver 
disease from other conditions in which serum alkaline 
phosphatase is elevated. Serum GGT levels are normal 
in Paget’s disease, rickets, and osteomalacia, and in 
children and pregnant women without a liver disorder.
 
Alkaline Phosphatase: Alkaline phosphatase activity 
in serum is primarily derived from three sources: 
Liver, bone, and the intestinal tract. Increased levels of 
alkaline phosphatase suggest cholestases.
Tests of Detoxification and  
Excretory Function
Bilirubin: Unconjugated hyperbilirubinaemia 
occurs in hemolytic disease, Gilbert’s syndrome and 
the Crigler-Najjar group of disorders. Conjugated 
hyperbilirubinaemia occurs in Dubin Johnson, Rotor 
No single test is able to provide an overall measure 
of the liver function. Instead, the group of values 
measured is interpreted collectively to determine the 
likelihood of liver disease, possible causes and the 
severity of the disease. Laboratory tests of the liver 
function can also be used to monitor the progress of 
the disease and the response to the treatments. 
Following is a brief description of the tests helpful 
in diagnosing and managing liver disorders done 
under the section of Chemical Pathology, Aga 
Khan University.
Tests Detecting Injury to Hepatocytes
Alanine transaminase (ALT) and Aspartate 
aminotransferase (AST): ALT is mainly found in 
the cytosol of the liver cell whereas AST is found in 
the cytosol and mitochondria. AST is also present in 
nearly the same levels in the heart, skeletal muscle 
and the liver. Therefore, mild and moderate liver 
damage gives high ALT and normal AST value and 
severe liver damage gives high AST /ALT blood test 
value. The AST/ALT ratio is approximately 0.8 in 
normal subjects. In particular, the AST is greater than 
the ALT in alcoholic hepatitis and the ratio is greater 
than 2:1. A high transaminase level is characteristic of 
liver cell death and the highest levels occur early in 
the disease (Fig 1). 
Routine and Special Liver Function Tests
Dr Lena Jafri
Chemical Pathology
Fig 1. Concentration of Transaminases in Various Liver Disorders.
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syndrome, and  in hepatocellular and cholestatic liver 
diseases (Table 1).
Ammonia: Ammonia is absorbed from the gut and 
incorporated into the urea and amino acids by the 
liver. If there is a severe hepatocellular disease or 
portal-systemic blood shunting, the blood levels 
of ammonia rise. An elevated blood ammonia level 
is a classic laboratory abnormality in patients with 
hepatic and encephalopathy which is present with 
altered mental status.
Tests of the Liver’s Biosynthetic Capacity
Serum Albumin/Total Protein: The liver is the sole 
site of albumin synthesis. The protein is not a good 
indicator of hepatic synthetic function in acute liver 
disease because of its half-life of 20 days. Albumin 
levels are decreased in malnutrition, trauma, nephrotic 
syndrome and in patients with ascites due to large 
volumes of distribution. The serum total protein value 
minus the albumin value gives the serum globulin 
level. Serum globulin can increase dramatically in 
chronic hepatitis and cirrhosis, and in the presence of 
hypoalbuminaemia. This emphasises the importance 
of measuring both albumin and total protein under 
these conditions.
Specific Etiological Tests of  
Liver Dysfunction
Alpha-1-Antitrypsin: Deficiency of this enzyme can 
lead to lung emphysema and liver disease. Decreased 
plasma levels of this protein may be associated with 
neonatal hepatitis, neonatal cholestasis, and cirrhosis 
in infancy, childhood or adulthood.
Alpha-Fetoprotein: Alpha-fetoprotein (AFP) is 
a glycoprotein that is normally produced during 
gestation by the foetal liver and yolk sac, the serum 
concentration of which is often elevated in patients 
with hepatocellular carcinoma. Elevated serum AFP 
may also occur in pregnancy, with tumours of gonadal 
origin, and may be seen in patients with chronic liver 
disease without hepatocellular carcinoma. 
LKM-1 Antibodies (IgG): LKM-1 antibodies are 
used in the diagnosis of auto immune hepatitis. 
These antibodies are not seen with type-1 patients of 
autoimmune hepatitis. LKM-1 antibodies can also be 
found in patients with chronic hepatitis C. 
Caeruloplasmin/Urinary Copper: Wilson’s disease 
results in liver cirrhosis. A characteristic feature 
is a low serum level of copper binding protein, 
caeruloplasmin and an increase in hepatic copper. If 
the caeruloplasmin is normal and Kayser-Fleischer 
rings are absent, but there is still a suspicion of 
Wilson’s disease, the next test is a 24-hour urine 
collection test for quantitative copper excretion. 
Diagnosis is confirmed by a liver biopsy.
Serum Ferritin/ Iron Studies: The presence of 
iron overload is suggested by elevations in the 
concentrations of plasma iron and ferritin and by an 
increase in transferrin saturation. Ferritin, a protein 
synthesised by the liver is the primary form of iron 
storage within cells and tissues. Measuring ferritin 
provides a crude estimate of iron stores in the body 
though in many cases notable inflammation can 
elevate serum ferritin. 
Other Analytes
Vitamin D: The two major forms of  Vitamin D; D2 and 
D3 are hydroxylated in the liver forming 25-hydroxy 
D. 25-hydroxy D is the key storage form and is known 
to provide the overall nutritional status of Vitamin D. 
Table 1. Concentration of Analytes in Prehepatic, Hepatic and Post Hepatic Jaundice
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Table 1. Concentration of Analytes in Prehepatic, Hepatic and Post Hepatic Jaundice
Liver disease impacts both the primary and 
secondary haemostatic pathways through a number 
of mechanisms. Historically, liver-disease associated 
coagulopathy has been considered a major contributor 
to bleeding complications. Both acute liver failure 
(ALF) and chronic liver disease (CLD) result in 
reduced synthesis of pro- and anticoagulant factors 
and are associated with thrombocytopenia and 
platelet dysfunctions. 
Routine correction of liver disease-associated 
coagulopathy is not required in non-haemorrhagic 
patients. 
Vitamin K deficiency is common in ALF and 
cholestatic liver disease and replacement of Vitamin 
K should be considered in these patients. Additional 
therapy may be required during episodes of variceal 
bleeding, surgery and prior to invasive procedures. 
However, the role of plasma and platelet infusion prior 
to invasive procedures is not well-established. 
Paracenteses and central venous access can be 
undertaken safely even in the presence of coagulopathy 
and thrombocytopenia, and bleeding post-liver biopsy 
is not predicted by abnormal laboratory markers. 
The British Committee for Standards in Haematology 
Blood Transfusion Taskforce (2004) suggested that 
there is insufficient evidence to support prophylactic 
transfusion of fresh frozen plasma (FFP) in those 
with a prolonged prothrombintime (PT) prior to liver 
biopsy. Furthermore, the response to FFP infusion in 
patients with liver disease is highly variable, with less 
Dr Farrukh Khan 
Haematology
Management of Coagulopathy Associated  
with Liver Disease
than 15 per cent of patients achieving an appropriate 
correction of PT following infusion of FFP in 
one study. The use of FFP can result in additional 
complications; large infusional volumes can lead 
to volume overload, with subsequent exacerbation 
of portal hypertension, ascites and intracranial 
hypertension, in addition to the risk of infection and 
transfusion related acute lung injury. 
In those with disseminated intra vascular coagulation 
(DIC) and bleeding, FFP administration may be 
useful. In this setting, in the presence of persistent 
hypofibrinogenaemia and continued bleeding 
following FFP, cryoprecipitate or fibrinogen 
concentrate may be used.
Platelet transfusion should be considered in the 
presence of bleeding and a platelet count of <10 x 
109/l or prior to invasive procedures in those with 
a platelet count of <50 x 109/l. Increments may be 
poor following platelet transfusion in those with 
hypersplenism, active bleeding or coexistent infection. 
Given the lack of evidence and efficacy in this area 
it may be more appropriate to adopt an expectant 
management strategy, whereby FFP is reserved for 
those who develop bleeding complications. However, 
this approach is considered too high a risk for some 
procedures, such as intracranial pressure monitor 
placement in ALF. Further research is required to 
determine an optimal management strategy. 
Recombinant Factor VIIa (rFVIIa) has been 
investigated as an alternative agent for the correction 
of PT in ALF and to reduce blood loss in those with 
In liver diseases, impaired hydroxylation by the liver 
can lead to Vitamin D deficiency. 
Haptoglobin: Haptoglobin is used to screen for 
and monitor intravascular hemolytic anaemia. In 
intravascular hemolysis, haptoglobin levels are 
reduced whereas in extra vascular hemolysis, the 
levels are normal. As haptoglobin is an acute-phase 
protein, any inflammatory process may increase the 
levels of plasma haptoglobin. Chronic liver disease 
may result in low haptoglobin levels.
Blood Urea Nitrogen: Since urea is synthesised in the 
liver, diseases of the liver without renal impairment 
result in low serum urea nitrogen, although the urea to 
creatinine ratio may remain normal.   
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Significance of Clinical and Laboratory 
Scoring Systems in Diagnosis of  
Disseminated Intravascular Coagulation in  
Chronic Liver Disease
Dr Natasha Ali 
Haematology
bleeding varices, prior to liver biopsy, liver resection 
and during liver transplantation. These studies have 
demonstrated that although rFVIIa administration 
leads to normalisation of the PT, there was no 
associated reduction in bleeding. It is not approved for 
use in liver disease and is associated with a significant 
increase in arterial thromboembolic events when used 
outside its approved indications. 
Prothrombin complex concentrates (PCC: containing 
Vitamin K-dependent coagulation factors) may have 
an advantage over FFP with smaller volume for 
delivery of factor replacement and rapid correction of 
haemostatic parameters. However, caution is required 
in patients with liver disease due to the risk of DIC 
and thromboembolic complications. There are no 
randomised controlled trials assessing the efficacy and 
reduction in bleeding risk with PCC in patients with 
liver disease.
Anti-fibrinolytic agents, including tranexamic 
acid, aprotinin and e-aminocaproic acid, have been 
used successfully to control bleeding during liver 
transplantation and reduce transfusion requirements 
in this setting. However, their routine use has recently 
been challenged and their role in liver disease outside 
the transplant setting has not been established yet. 
The use of desmopressin (1-deamino-8-d-arginine-
vasopressin, DDAVP) has been investigated in liver 
disease but no improvement in clinical outcome 
was seen in those with variceal bleeding or those 
undergoing transplantation. 
There may be a future role for thrombopoietin mimetics 
in the treatment of thrombocytopenia associated with 
CLD. A phase 2 study of Eltrombopag in patients 
with HCV-associated cirrhosis demonstrated its 
efficacy in raising platelet counts sufficiently to allow 
commencement of antiviral therapy. 
Further clinical trials are awaited; there may be 
a further role for these agents in amelioration of 
thrombocytopenia in patients with CLD prior to 
procedural interventions.
The liver is the most important organ involved in the 
regulation of haemostasis. Most of the clotting factors, 
their inhibitors and a number of proteins responsible 
for fibrinolysis are produced in the liver, therefore, 
liver disease impacts both primary and secondary 
haemostatis pathways through a number of different 
mechanisms.  Abnormalities of the clotting cascade 
are the predominant features of acute and chronic 
liver disease. In few patients with hepatic disease, 
physicians are faced with diagnostic challenge of an 
underlying bleeding or thrombotic diathesis due to 
overlap between various clinical syndromes including 
Disseminated Intravascular Coagulation (DIC). 
According to the International Society of Thrombosis 
and Haemostasis (ISTH), DIC is a syndrome 
characterised by a systemic intravascular activation 
of coagulation, with loss of localisation, arising from 
different causes. It can originate from and cause 
damage to the microvasculature, which if sufficiently 
severe can produce organ dysfunction. ISTH also 
proposed that the working definition of DIC can be 
divided into two phases: 
a) Non-overt DIC: represents subtle haemostatic 
 dysfunction
b) Overt DIC: de-compensated phase of non-overt  
 DIC
Events responsible for DIC in liver disease include 
liver necrosis, impaired endotoxin clearance, surgery, 
shock and ascites recirculation. DIC can be recognised 
as a syndrome suggested by clinical signs and 
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laboratory tests. The characteristic laboratory findings 
include: prolonged prothrombin time (PT), activated 
partial thromboplastin time (APTT), thrombin time 
(TT), increased levels of fibrin related markers (Fibrin 
degradation products, D-Dimer), decreased platelet 
count, fibrinogen level, plasma coagulation factors 
and their inhibitors. More specialised and useful 
tests include: prothrombin activation fragments and 
thrombin-antithrombin complex (TAT). 
In 2001, ISTH proposed two separate scoring 
systems for overt and non-overt DIC.  The overt DIC 
score consists of a five-step diagnostic algorithm in 
which a specific score - reflecting the severity of the 
abnormality found -  is given to each of the laboratory 
tests (Table 1). A score of five or more is considered 
to be compatible with DIC, whereas a score of less 
than five may be indicative (but not affirmative) 
of non-overt DIC. Similarly, using certain clinical 
and laboratory findings (Table 2), a score of five or 
greater is compatible with non-overt DIC which could 
diagnostically define patients with a poor prognosis 
due to haemostatic dysfunction, independent of 
developing overt DIC.
Table 1. ISTH Score System for Overt DIC
Interpretation: A score of >5 is compatible with non-overt DICt he higher the score the more likely that 
non-overt DIC is present All the tests required for DIC scoring except fibrin monomer are available at AKU clinical 
laboratories.
Interpretation: A score of >5 is compatible with overt DIC.
Table 2. ISTH Score for Non-overt DIC
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Echinococcosis or hydatid disease is caused by 
tapeworm Echinococcus most commonly as species 
E. granulosus and E. multilocularis. Humans are the 
incidental dead-end hosts due to accidental ingestion 
of eggs. The oncospheres hatch in the intestine, enter 
the blood stream to migrate to the liver and other 
viscera where a fluid filled multi-layered cyst with 
protoscolices develops a hydatid cyst.
Infection of the liver frequently produces no symptoms 
and remains quiescent for years or produces mass 
effects. They rarely rupture into the biliary tract or the 
peritoneal cavity. The right lobe is affected in 60-85 
per cent of the cases. Secondary bacterial infection of 
the cysts results in liver abscesses.
Microscopy: The saline wet preparation demonstrates 
the daughter cysts or brood capsules with protoscolices 
in surgically removed tissues. The inner lining of the 
cyst is a germinal membrane from which numerous 
daughter embryos develop. These form minute 
polypoid structures (brood capsules) that line the inner 
reproductive membrane from which large number of 
daughter cysts are produced. When embryos break 
free from the membrane and float in the fluid within 
the cyst, they are known as hydatid sand (Fig 1). Under 
the microscope, each grain of sand is in fact a tiny 
embryonic beginning of a new tapeworm, complete 
with an inverted scolex and a rostellum armed with 
hooklets. 
Serology: Serology is a useful tool for primary 
diagnoses as well as follow-up after treatment. Most 
immunodiagnostic techniques involve the detection 
of Echinococcus specific antibody in the serum of 
suspected patients using a variety of crude antigens. 
The problem with methods using crude antigens is 
the serologic cross-reactivity of Echinococal antibody 
test. Additional tests using recombinant or purified 
species-specific antigens may complement the 
serological diagnoses.
False Positive and False Negative Results: Serologic 
testing produces both false positive and false negative 
results.
False positive reactions are more likely to happen in 
the presence of other helminth infections, cancer, and 
immune disorders. False negative results occur with 
varying frequency depending on the site of the lesion 
and the cyst’s integrity and viability. Cysts in the liver 
more commonly (85-95 per cent) elicit an antibody 
response than cysts in the lung (65 per cent). Thus, 
a negative serologic test generally does not rule out 
echinococcosis. Brain, eye, and splenic cysts often 
do not produce detectable antibodies, whereas bone 
cysts are frequently associated with positive serology. 
Serology is less likely to be positive with cysts at any 
site if  the cysts are intact, calcified or nonviable. 
Children and pregnant women have negative serology 
more frequently than other patient populations.
Serologic Methods: A number of techniques 
are currently employed, these include 
indirect hemagglutination (IHA), indirect 
immunofluorescence, latex agglutination, double 
diffusion immunoelectrophoresis, counter-current 
immunoelectrophoresis (CIEP), radioimmunoassay 
Laboratory Diagnosis of Hydatid Disease
Dr Sana Rajper and Dr Joveria Farooqui 
Microbiology
Fig 1. Wet preparation of liver abscess aspirate showing hydatid sands 
of echinococcus spp. (x 40 magnification).
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(RIA), enzyme-linked immunosorbent assay 
(ELISA), enzyme-linked immunoelectrotransfer blots 
(EITB), enzyme-linked immunoelectrodiffusion assay 
(ELIEDA), time-resolved fluoroimmunoassay (TR-
FLA) and immunoblot.
Screening Test: The methods most frequently 
employed for initial screening tests are IHA and 
ELISA. Currently, our laboratory is using the IHA 
method for detection of Echinococcal antibody.
Indirect Hemagglutination Test (IHA) :  The indirect 
hemagglutination test aids in the qualitative detection 
and quantitative determination of specific antibodies to 
Echinococcus granulosus in human serum. It is based 
on the principle of indirect erythrocyte agglutination 
(Fig 2).
Serum dilutions of 1:32 to 1:64 and higher provide 
diagnostically useful titers. Mid-range serum titers 
lie between 1:512 and 1:2048. Low serum titers (1:32 
to 1:128) should only be accepted as positive when 
evaluated in conjunction with a second serological. 
method (for example, CFT, IFT or ELISA). 
Laboratory Diagnosis of Amoebiasis
Amoebiasis is caused by the protozoan, Entamoeba 
histolytica. The parasite exists in two forms: a cyst stage, 
which is the infective form, and a trophozoite stage, 
which is the form that causes invasive disease. Majority 
of infections occur in developing countries due to poor 
socio-economic conditions and low sanitation levels. 
Amoebic liver abscess is the most common extra- 
intestinal manifestation of amebiasis. Amoebae 
establish hepatic infection by ascending the portal 
venous system. Patients are in the acute stage after one 
to two weeks of fever and right upper quadrant pain. 
Concurrent diarrhoea may also occur. Occasionally, 
patients have a more chronic presentation with months 
of fever, weight loss, abdominal pain, hepatomegaly 
and anaemia. Hepatic vein and inferior vena cava 
thrombosis secondary to amoebic liver abscess may 
also be present.
Laboratory Diagnoses
 
Microscopy: Amoebic liver abscesses contain 
acellular, proteinaceous debris, an anchovy paste, and 
a chocolate coloured fluid, consisting predominantly 
of necrotic hepatocytes. If an unstained saline amount 
of the aspirate is observed under the microscope 
within 2 hours, trophozoites may be seen in fewer 
than 20 per cent of cases and are often present only 
in the peripheral parts of the abscess, invading and 
destroying adjacent tissue. 
Serologic Testing: Serum antibodies will be 
detectable in 92-97 per cent of cases presenting 
with amoebic liver abscess. Eventually 99 per 
cent of the patients will have positive antibody tests, 
but serologic testing may be negative in the first 
seven days. Up to 25 per cent of uninfected 
individuals in endemic areas have antiamoebic 
antibodies due to previous, often undiagnosed 
infection with E. histolytica. Consequently, positive 
serology in these populations is not nearly as 
helpful, although negative serology still assists 
in excluding this infection. Currently, we are 
performing IHA test for diagnosing amoebiasis. 
Other methodologies are agar gel diffusion and 
counter-immunopheresis which are less sensitive.
Dr Sana Rajper and Dr Joveria Farooqui
Microbiology
Fig 2. Indirect Heamagglutination Test for the diagnosis of both Echino-
coccal Liver Cyst and Amoebic Liver Abscess.
 a-A
 a-B
 a-A/B
nc
 a-D
 a-D
10
January 2011, Vol. 36, Issue 1
Indirect Heamagglutination Test (IHA): It aids in the 
qualitative detection and quantitative determination 
of specific antibodies to Entamoeba histolytica in 
human serum. It is based on the principle of indirect 
erythrocyte agglutination (refer to Fig 2 on page 9).
Serum dilutions of 1:32 and higher provide titers 
useful for diagnosis that indicate the presence 
of an invasive amoebiasis. Mid range serum 
titers lie between 1:256 and 1:2048. Low positive serum 
titers ranging from 1:32 to 1:54 should only be accepted 
as positive when evaluated in conjunction with a 
second serological method like immunoflourescence. 
Titers below 1:32 are generally considered to exclude 
an invasive amoebiasis.
For this reason, the method is especially well 
suited for the differential diagnosis of invasive 
amoebiasis in cases of abdominal pain that 
has not been clearly diagnosed.
Pyogenic liver abscesses are often caused by anaerobic 
bacteria. As many as 25 per cent of the bacteriologic 
yield from pyogenic liver abscesses comprise of 
anaerobes. Multiple abscesses are difficult to drain 
and therapy is primarily medical. Antibiotic therapy 
of complicated abscesses requires growing causative 
pathogens and subsequent sensitivity testing. 
Growth of anaerobes in the microbiology laboratory 
is often challenged by prolonged laboratory transport 
times resulting in death of anaerobes, prevalence 
of fastidious anaerobes in clinical specimens, and 
differing growth requirements of different anaerobes 
unmet by various anaerobic culture systems. The latter 
issue has been overcome by the use of automated 
anaerobic chambers. Such chambers allow for hassle- 
free culture of anaerobes without the added cost of 
multiple gas-generating kits and anaerobic jars. 
Additional provision for workspace in the chambers 
allows for processing, sensitivity testing and 
identification of anaerobes within the anaerobic 
environment of the chamber without having to remove 
bacterial Petri plates.  
Incorporating such automated anaerobic chamber 
systems in microbiology laboratories increases the 
yield of anaerobic isolates and allows for appropriate 
sensitivity testing and identification of anaerobes in 
clinically relevant specimens (Fig 1).
Improvement of Bacteriological Yield of Liver 
Abscess by Use of Anaerobic Chambers
Dr Sadia Shakoor 
Microbiology
Fig 1. Anaerobic Chamber in use at Aga Khan University Clinical Microbiology Laboratory.
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Radiofrequency ablation, commonly referred to 
as RFA, is a minimally invasive treatment for liver 
cancer. It is an image-guided procedure which 
produces coagulative necrosis of tumor through local 
tissue heating (Fig 1 and Fig 2).
In this technique various imaging modalities such as 
ultrasound, computed tomography (CT) or magnetic 
resonance imaging (MRI) are used to help guide 
a needle electrode into a lesion. High-frequency 
electrical currents are then passed through the 
electrode, creating heat that destroys the tumour cells. 
Indications
a) Hepatocellular carcinoma. 
b) Liver metastasis, most commonly colorectal,  
 especially if the patient is not an operative candidate.
Inclusion Criteria for Hepatocellular 
Carcinoma (HCC)
a) Single tumour < 5cm. (lesions > 5cms can 
 be considered for RFA alone or in combination 
 with TACE. However, there is a weak level III 
 evidence up till now and can be considered as 
 pilot in our institution). 
b) Multicentric < 3 lesions, each < 3 cm.
c) Child-Pugh class A or B.  
d) Tumours accessible by percutaneous route.
Inclusion Criteria for Metastatic Disease 
of Colorectal Cancer
a) Oligometastases to the liver < 5cm.  (those 
 patients with metastatic disease may qualify 
 if extrahepatic disease is deemed curable). 
b) When multiple < 3 lesions, each < 3 cm.
Exclusion Criteria for HCC and  
Metastatic Disease
a)  Single mass (primary or metastatic) > 5 cm (in  
 longest axis).
b)  When > 1 lesions any one lesion  > 3 cm (in  
 longest axis).
c)  When  > 3 lesions  (NOTE: Should not   
 be considered as absolute contraindication if 
 successful treatment of all metastatic deposits  
 can be accomplished).
d)  Tumour abutting a major hepatic biliary duct or  
 < 1 cm from the main biliary duct.
e) When < 2 cm from large hepatic vein or portal  
 veins.
f) Tumour adjacent to hepatic hilum and   
 gallbladder.
g) Exophytic location of the tumour (due to the risk  
 of tumour seeding).
h) Along the liver surface or < 1 cm deep to 
 the liver capsule (hydrodissection can still 
 be considered) [Relative Contraindication].
i) Lesions adjacent to GIT, kidney, adrenal 
 (hydrodissection can still be considered). 
 [Relative Contraindication].
j) Extrahepatic spread (unless curable) [Relative 
 Contraindication].
Radiofrequency Ablation of Liver Tumours
Dr Rana Shoaib and Dr Muhammad Azeemuddin 
Radiology
Fig 2. A schematic diagram showing an RF needle electrode deployed in 
a liver tumour.                                 
Fig 1. Needles used for RFA.
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k) Intrahepatic bile duct dilation [Relative 
 Contraindication]
l) Evidence of vascular invasion,
m) Refractory coagulopathy
n) Ascites [Relative Contraindication]
Anaesthesia
This procedure is generally performed using local 
anaesthesia and mild sedation. However, deep 
sedation may be used if necessary.
Complications
RFA is a relatively low-risk procedure with a low 
rate of morbidity and mortality. However, few 
complications are associated with RFA. These include 
postablation syndrome which presents with low-grade 
fever, delayed pain, malaise, myalgia, nausea, and 
vomiting.
Other rare complications include shoulder pain, 
Cholecystitis, bile duct injury, Hemorrhage, 
Pneumothorax, Hemothorax or Pleural effusion, 
Hemobilia, and Infection.
RFA is considered superior to ethanol injection in the 
treatment of small HCC. RFA results in a higher rate 
of complete necrosis and requires fewer treatment 
sessions than percutaneous ethanol injection (Fig 3 
and Fig 4).
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Radiofrequency ablation (RFA) at AKUH
Fig 3. First case of RFA at AKUH:  41-year-old male with HCV, early 
child’s B cirrhosis, A small hepatoma in liver (a) He was successfully 
subjected to RFA treatment (April, 2010) in Radiology without any major 
complication (b and c) Post RFA CT scan (d) Typical ring enhancement 
(inflammatory) and lesion is entirely avascular.
Fig 4. Another male patient with lesion in left lobe of liver (a) RFA per-
formed under CT guidance (b) Needle can be seen.
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The arrival of Herceptin for the treatment of HER2 
amplified breast cancer patients has promoted 
considerable interest in the biology of HER2 
receptor. Recent studies have established HER2 as 
an independent prognostic and predictive factor and a 
potential therapeutic target. Following is an overview 
that addresses some basic and frequently asked 
questions about HER2 gene amplification, and its role 
in breast cancer management. 
What is HER2?
HER2, discovered in 1980, is a cell surface receptor 
that belongs to the epidermal growth factor receptor 
(EGFR) family. According to HUGO nomenclature 
committee, its official name is ERBB2. It is located 
on chromosome 17q12. Other members of the EGFR 
family include HER1, HER3 and HER4. Tyrosine 
kinase activity that initiates HER2 dependent signaling 
pathways resides in its cytoplasmic domain (Fig 1). 
Activated HER2 receptor phosphorylates a variety of 
substrates, which leads to initiation of intracellular 
signalling mechanisms involved in tumorigenesis. 
Why HER2 is important in breast cancer?
According to a recent survey, the annual incidence 
of breast cancer worldwide in females contributes 
approximately 30 per cent to the total number of 
cancer cases reported each year. Whereas, in 25-30 
per cent breast cancer patients’ gene amplification 
of HER2 confers rapid tumour growth, lymph node 
metastases, high risk of post-surgery recurrence and 
poor survival. Moreover, scientific literature illustrates 
that patients with early stage disease and favourable 
tumour features also experience aggressive outcome 
in the presence of HER2 gene amplification, which 
makes HER2 a significant player in breast cancer 
management.
How HER2 is detected in breast cancer?
HER2 can be monitored by immunohistochemistry, 
real-time PCR and FISH at protein, messenger RNA 
and DNA levels respectively.
  
a) For initial screening, immunohistochemistry 
 (IHC) is the choice for relative quantification of 
 HER2 protein (receptors) because it is rapid, 
 easy to perform and has a short turnaround 
 time with the added advantage of reliably 
 excluding ‘negative (0 or 1+)’ cases from 
 ‘strong positive or 3+’ cases. Level of surface 
 bound HER2 protein in breast cancer is 
 evaluated in the invasive component by 
 measuring the intensity of membrane staining. 
 HER2 immunostained slides are scored on   
 a scale of 0-3+ based on the proportion of cells 
 staining, completeness and intensity of 
 membrane staining (Fig 2). A score of 2+   
 is considered as equivocal and require further  
 confirmation by additional tests. Current ASCO  
 guidelines recommend first to examine HER2  
 protein status by IHC and in case of equivocal  
 staining HER2 gene should be quantified by  
 FISH technique. 
b) HER2 gene amplification status in formalin fixed 
 paraffin embedded (FFPE) tissues can be 
 established by FISH assay. It provides direct  
 visual examination of gene copy number 
HER2 in Breast Cancer: FAQs
Dr Tariq Moatter and Dr Shahid Pervez 
Molecular Pathology and Histopathology
Fig 1. Diagram of HER2 receptor. Domains I-IV constitutes ECD. A sin-
gle transmembrane domain spans the cytoplasmic membrane. * indicates 
the site of PKC-mediated threonine phosphorylation. N and C represent 
amino and carboxyl terminal lobes of kinase domain. Arrow points to the 
site targeted by Herceptin (redrawn from Landgarf, BCR 2007, 9:202). 
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 in the inter-phase nuclei. A DNA probe 
 complimentary to HER2 gene and a second 
 control probe specific to the centromeric region 
 of chromosome 17 are hybridised to the 
 previously processed FFPE tissue. Probe signals 
 are searched in the invasive tumour, which is 
 marked with the help of a corresponding H&E 
 stained slide. In the invasive component of the 
 tumour nuclear morphology is observed using 
 DAPI filter. At least 20 non-overlapping cells 
 from two different regions are scored. A non-
 amplified tissue shows two HER2 signals and  
 two control probe signals, whereas an amplified  
 HER2 may exhibit two type of signal patterns; 
 a) clusters or patches of signals due to 
 homogenously staining regions, b) individual
 and discrete signals, which indicate double 
 minute chromosomes. In addition, presence of 
 multiple HER2 and control probe signals that
 indicate polysomy 17 (Fig 3). 
c) Chromogenic in situ hybridisation (CISH) is an 
 alternative to FISH. In CISH assay a HER2 
 specific DNA probe binds to tumour DNA. The 
 probe is detected followed by multiple treatments 
 concluding with application of antibody linked to 
 horseradish peroxidase enzyme and DAB 
 chromogen (Fig 4). In contrast to FISH,  
 signal detection of CISH is based on bright  
 field microscopy.  A major advantage of CISH  
 over FISH technique is that HER2 signals 
 are observed in relationship to the histological 
 architecture. Secondly, as staining is permanent 
 and not sensitive to light, slides can be stored 
 for a longer duration. A recent enhancement 
 in CISH technology is the introduction of a two-
 colour CISH, which has improved interpretation 
 of borderline cases. 
What is the Concordance level between 
FISH and IHC?
High concordance (> 90 per cent) between IHC and 
FISH is noted when IHC are 0 or 1+ (negative) and 3+ 
(positive). Cases with IHC 2+ are considered equivocal 
and should be tested by FISH assay. In these cases, 
FISH is considered a gold standard. Among the IHC 
2+ cases tested by FISH assay, approximately a quarter 
of the cases show gene amplification. However, on the 
basis of current literature, it is concluded that around 
20 per cent of the current testing by various methods 
may be inaccurate resulting in discrepancies between 
Fig 2. Photographs illustrating immunohistochemical staining of HER2 receptors along with estimated staining scores. Courtesy: AKUH
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IHC and FISH results. Following are the possible 
reasons for this discrepancy usually resulting in IHC 
3+ with negative FISH.
a) Heterogeneity of antigenic expression as in 
 otherwise IHC 3+ cases areas of IHC 2+ may 
 also be present focally. It is important therefore to 
 do FISH on strong positive tumour foci.
b) Over and under fixation of the tissue resulting in 
 masking or loss of antigens. Optimum fixation 
 time is between 6-24 hours in 10 per cent buffered 
 formalin depending on the size of the tumour.
c) HER2 protein over expression can occur without 
 gene amplification because of increased 
 transcriptional or post transcriptional activity,  
 mRNA stabilisation or the presence of 
 chromosome 17 polysomy.  
d) Selection of HER2 antibody and use 
 of standardised or nonstandardised assays.
e) Interpretation by the reporting pathologist as 
 current score given on morphologic 
 assessment alone is largely subjective.
Tips and Tricks
a) HER2 assessment shall only be done 
 on infiltrative component.
b) No grade 1 carcinoma breast like tubular
 carcinoma should be HER2 positive.
c) No HER2 positivity in Medullary carcinoma  of 
 breast.
d) No HER2 positivity in classic 
 lobular carcinoma breast.
e) Changing of magnification from low to 
 high power precludes 3+ IHC score.
f) In case of polysomy if absolute copy number
 on FISH is > 6 may qualify for amplification.
What is Polysomy 17?
Polysomy 17 is defined as the presence of three or 
more copies of chromosome 17 in a cell. It is a frequent 
feature of breast carcinoma. According to a report, 
polysomy 17 is seen in 20-40 per cent of invasive 
breast carcinomas. However, the association between 
over expression of HER2 protein and polysomy 17 
is controversial. Some reports link polysomy 17 to 
HER2 over expression, whereas other publications 
show no influence on HER2 protein expression. A 
a)
b)
e)c)
d)
Fig 3. Representative photographs of FISH assay results. (a) two red signals of HER2 and two green signals of chromosome 17 (CEP) so normal 
with no amplification;  (b) one red signal of  HER2  and one green signal of chromosome 17 (CEP) so monosomy with no amplification.;  (c) mul-
tiple red signals ( mean of 22) of HER2 and  two green signals consistent with strong amplification;  (d) multiple red signals ( patches) of HER2 
and two green signals consistent with strong amplification; (e) multiple red signals ( mean of 4) of HER2 with multiple green signals (mean of 4)  
represent polysomy. Courtesy: AKUH
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scientific report has suggested that a high HER2 copy 
number observed in polysomy 17 in invasive breast 
carcinomas is a significant contributing factor in 
HER2 protein over expression. However, currently 
polysomy 17 positive tumours are ineligible for 
trastuzumab therapy.
What is Trastuzumab and its Mechanism 
of Action? 
The knowledge of molecular mechanisms that 
operate in breast cancer has enhanced significantly 
in the recent years leading to refinement of therapies 
that target signalling molecules. Breast cancer 
patients who over express HER2 gene can benefit 
from one such treatment that is a recombinant 
monoclonal antibody called trastuzumab (Herceptin). 
This antibody is developed by linking the antigen 
binding regions of mouse anti-HER2 monoclonal 
antibody into a human IgG. Trastuzumab binds 
to the extracellular domain of the HER2 receptor 
(Fig 1). Although, the mode trastuzumab’s action 
is not completely worked out but current literature 
suggests that it can cause HER2 receptor down 
regulation, inhibit intracellular signalling or even block 
receptor cleavage.  Trastuzumab has also been shown 
to inhibit angiogenesis and decrease microvessel 
density in vivo.  In patients with early stage disease, 
trastuzumab has significantly improved disease free 
survival and overall survival rates. According to 
available reports, trastuzumab can produce response 
rates up to 35 per cent in selected metastatic breast 
cancer patients.
Can HER2 Levels Predict Disease and 
Treatment Outcome? 
HER2 gene amplification is an independent marker of 
inferior prognosis in breast cancer and is associated 
with high-grade tumours, lymph node metastasis 
and shorter disease-free and overall survival. Over 
expression of HER2 predicts success of trastuzumab 
therapy, which is manifested by lower recurrence 
rate and improved survival. On the other hand, the 
role of HER2 expression in predicting chemotherapy 
response is still debatable. So far, in several studies 
resistance to CMF (cyclophosphamide, methotrexate, 
and fluorouracil) chemotherapy has been reported 
in patients over expressing HER2. Conversely, 
HER amplification predicted a better response to 
anthracyclenes. Moreover, patients over expressing 
HER2 gene demonstrated a favourable response to 
taxanes. In estrogen receptor positive breast cancer 
patients, HER2 over expression has been implicated in 
resistance to tamoxifen treatment as well, highlighting 
the predictive value of HER2 in breast cancer.
Fig 4. Detection of HER2 gene amplification by CISH. Multiple dark brown dots in 
the nuclei indicate multiple HER2 gene copies consistent with gene amplification. 
Courtesy: AKUH
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In our flow cytometry practice at AKUH, 
bone marrow and/or peripheral blood samples 
from patients with anaemia, leukopaenia, 
thrombocytopaenia, or leukocytosis are routinely 
submitted for immunophenotypic evaluation of a 
possible hematolymphoid neoplasm.  Lymph node 
and extranodal tissue biopsies can also be evaluated 
in patients with lymphadenopathy whose differential 
diagnosis includes lymphoma.  Body fluids are also 
frequently submitted for the diagnosis or staging of 
patients with suspected lymphoproliferative disorder.
The first step is to establish a diagnosis of 
a hematolymphoid neoplasm (e.g. actue 
lymphoblastic leukemia/lymphoma) and then 
flow cytometry can be used to monitor status of 
disease and/or response to prior therapy and most 
importantly evaluate for minimal residual disease 
(MRD) once the disease is in clincal remission. 
Acute lymphoblastic leukemia which includes 
precursor-B cell ALL and precursor-T cell ALL are 
routinely diagnosed at AKUH.  Precursor B-cell 
ALL comprises of 85 per cent of childhood ALLs 
and 75 per cent of adult ALLs with the remainder 
being precursor T-ALL. Precursor B-cell ALL are 
lymphoblasts which are committed to the B-cell 
lineage.  On flow cytometric studies, the B lineage is 
established by the positive expression of CD19, CD22 
and CD79a.  CD20 which is a highly specific marker 
for B-cell lineage is expressed in one-third to one-half 
of precursor B-cell ALLs.  Surface immunglobulins 
are generally absent.  CD34 and TdT (Fig 1) which 
are expressed in 80 per cent and 98 per cent of 
precursor B-cell ALLs respectively are markers of 
immature phenotype, but do not distinguish between 
B and T lineage.  Finally, CD10, although not a 
reliable discriminator between B and T lineage, has 
Role of Flow Cytometry in the Evaluation 
of Minimal Residual Disease of Acute 
Lymphoblastic Leukemia
Saifullah Khan, Sarwat Kashif, Afshan Pervaiz 
Histopathology
Fig 1.  Precursor B-cell ALL (prior therapy).  78% lymphoblasts show 
positive expression for TdT (quadrant B4).  The B-cell lineage had been 
determined which is not shown.
Fig 2.  Minimal Residual Disease (MRD) following therapy (day 28) 
from same patient (Fig 1).  <0.01% lymphoblast present showing posi-
tive expression for TdT (quadrant B4).
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cryopreservation of umbilical cord stem cells. A 
lucid presentation on NAT, emphasising the 
importance of this technique in the screening of blood 
donors was given by Dr Bushra Moiz. This technique 
which will shortly be available at Aga Khan University 
clinical laboratories promises the enhanced safety of 
blood products.
The CME seminar titled Recent advances in Blood 
banking was organised by the section of Haematology, 
Department of Pathology and Microbiology on 
April 28, 2010. Prof. Mohammad Khurshid 
introduced the objective of the CME and highlighted 
the importance of advances in blood banking like 
Nucleic acid amplification testing (NAT) and 
Meeting Reports:
Clinical Laboratory Continuing  
Medical Education Seminar
Reported by Dr Raihan Sajid 
Haematology
Professor Mohammad Khurshid addressing the audience at the CME 
Seminar
Participants at the CME seminar
a positive expression which carries a prognostic 
significance. In Precursor T-cell ALL, cytoplasmic 
CD3 is the single most sensitive and specific marker 
of T-lineage differentiation. Surface CD3 is specific, 
but less sensitive. Surface CD7 is expressed in 
virtually in all cases of T-cell ALL, however it is not 
specific and its positive expression is seen in Acute 
myeloid leukemia. Immaturity in precursor T-cell 
ALL is established by expression of Tdt and CD34.
Response to therapy in patients with acute leukemia 
has traditionally been evaluated morphologically; 
less than 5 per cent blasts in the bone marrow are 
considered to have achieved morphologic complete 
remission. Minimal residual disease (MRD) refers to 
the presence of small numbers of residual neoplastic 
cells following therapy, at levels below the threshold 
of detection of conventional morphologic anaylsis. 
Flow cytometry is an analytic method (Fig 2) which has 
a sensitivity of at least one  leukemic cell among 10,000 
normal cells in ALL. The detection of MRD in a patient 
who is in morphologic remission following therapy, 
may be an adverse prognostic factor. The strategy 
is to analyze for antigenic combinations or isolated 
antigens that are not detectable in normal bone 
marrow e.g. cytoplasmic CD3 and TdT in precursor 
T-ALL. In cases of acute lymphoblastic leukemias, 
we have introduced a panel in the flow cytometric 
immunophenotyping (which includes Tdt) which 
will be useful in detecting MRD following therapy.
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Moderator, Dr Salman Adil along with speakers Dr Mohammad Kashif, 
Dr Mohammad Usman, Dr Bushra Moiz and Dr Raihan Sajid.
Dr Raihan Sajid explained the concepts of 
cryopreservation of stem cells and the setting up of 
this facility at Aga Khan University in the near future. 
Dr Mohammad Usman Shaikh elaborated the usage 
of irradiated blood products in the clinical setting. He 
further stressed that all the patients undergoing bone 
marrow transplantation should receive irradiated 
red cells and platelets. Luckily, the AKU blood 
bank offers this facility to all patients who are under 
treatment outside AKU hospital. The proceedings 
were concluded by Dr Salman Adil who also 
moderated the question answer session at the end. 
The seminar was well attended and more than 430 
participants from different hospitals and institutions 
of Karachi participated. 
The World blood donor day was celebrated on June 
14, 2010 under the auspices of Aga Khan University 
Blood bank to appreciate voluntary blood donors for 
their selfless sacrifice in saving the lives of needy 
patients. The function started with Prof. Mohammad 
Khurshid giving the welcome address. This was 
followed by an interesting presentation by Dr Bushra 
Moiz on New blood for the world which highlighted 
the significance of recruitment and retention of young 
voluntary donors. Later, Mr Anwar Ajani talked about 
the activities of Karachi Lion’s club for setting up 
Prof Naila Kayani , Chairperson of the Department of Pathology and 
Microbiology presented a shield of appreciation to Mr Anwar Ajani
Dr Natasha Ali giving the prize to one of the participants
blood procurement camps. One of the patients, who 
had benefitted from the bank, thanked the voluntary 
blood donors for their contribution to the society. 
The event ended with an interesting quiz program. 
Dr Natasha Ali and Dr Raihan Sajid hosted the prize 
distribution ceremony. 
World Blood Donor Day 
at AKU Blood Bank
www.aku.edu/akuh/hs/cs/pathology.shtml
